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PCR localization of angiotensin H receptor and angiotensinogen
mRNAs in rat kidney. Recent studies revealed that angiotensin H (Ang
II) interacts with two pharmacologically different subtypes of cell
surface receptors. Type I Ang II (AT1) receptor is characterized by
signal transduction mediated through G protein and phospholipase C. In
this study, the micro-localization of mRNAs coding for AT1 receptor
and angiotensinogen was carried out in the rat kidney, using an assay of
reverse transcription and polymerase chain reaction (RT-PCR) in
individual microdissected renal tubule segments along the nephron,
glomeruli, vasa recta bundle, and arcuate arteries. Large signals for
AT1 receptor were detected in the glomerulus, proximal convoluted
tubule (PCT), proximal straight tubule (PST), cortical collecting duct,
and vascular system. Small signals were also seen in medullary thick
ascending limb, outer medullary collecting duct, and inner medullary
collecting duct (IMCD). Angiotensinogen mRNA is expressed largely in
PCT, PST, and a small amount in glomerulus and vasa recta. Our data
demonstrate that Ang II could be produced locally in proximal tubule
and vasa recta bundle, and that the AT4 receptor was widely distributed
not only in the glomerulus and vessels but also in tubules from PCT to
IMCD.
The renin-angiotensin system plays a major role in the
regulatory mechanism for electrolytes and blood pressure con-
trol. Angiotensin II (Ang II) has important actions on the kidney
that include regulation of renal vascular resistance, glomerular
filtration [1], tubular epithelial transport [2, 31, and medullary
blood flow [4].
Recently, two binding sites for Ang II have been identified
pharmacologically [5]. Although both bind Ang II and most of
its peptide analogs with the same avidity, type I Ang II receptor
(AT1 receptor) has high affinity for the selective non-peptide
antagonist Dup753, while the type II Ang II binding site has
high affinity for non-peptide antagonist PD 123177 [6, 7].
Sasaki et a! [61 and Murphy et al [7] have successfully cloned
AT1 receptors, respectively from cultured bovine adrenal zona
glomerulosa cells and from rat aortic vascular smooth muscle
cells. These receptors possess a seven transmembrane domain
structure, which is typical of G protein-coupled receptors. Ang
II binding to AT1 receptor causes a transient increase in the
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concentration of intracellular calcium and production of inositol
phosphate [6, 7].
In Northern blot analysis, mRNA for AT, receptor is de-
tected in the kidney [6, 7]. But it is not known which parts of the
kidney express AT1 receptor mRNA. There has been contro-
versy about the localization of Ang II receptor in the kidney,
which was determined by autoradiographic technique or micro-
dissection technique. Mendelsohn et al [81 reported, using an
autoradiographic technique, that a high density of binding was
found over glomeruli and vasa recta bundle, and that low levels
of Ang II binding sites were seen in the outer cortex. Recently,
Sechi et al [9] reported that Ang II binding sites were found in
glomeruli and medullary vascular bundles, and these bindings
were almost completely inhibited by Dup 753. On the other
hand, Mujais, Kauffman and Katz [10] studied the binding sites
of '251-Ang II along microdissected nephron segments. They
found specific binding sites not only in proximal tubule but also
in thick ascending limbs, distal convoluted tubules, cortical
collecting ducts, and medullary collecting ducts. But these
studies did not examine the mRNA distribution of AT, recep-
tors. It seems interesting to determine the precise localization
of AT, receptor mRNA, which is reported to play physiological
roles, along the nephron segments.
Studies using Northern blot analysis have shown that an-
giotensinogen mRNA is expressed in the renal cortex and
medulla [11, 12]. Ingelfinger et al demonstrated angiotensinogen
mRNA to be localized mainly in the renal proximal tubule [131.
That study, however, did not find substantial amount of an-
giotensinogen mRNA localization in the medulla. Local an-
giotensinogen may exert an autocrine-paracrine influence on
renal function. Information on angiotensinogen mRNA local-
ization can provide insight into the organization and biology of
the local renin-angiotensin system.
Recently, Moriyama et al [14] and Terada et al [15] intro-
duced a new method for measurement of relative levels of
specific mRNA in single microdissected renal tubules, using the
polymerase chain reaction (PCR) coupled to reverse transcrip-
tion (RT-PCR). Using this technique, relative quantitation of
mRNA coding for peptide hormone receptor was performed
from only 2 mm length of renal tubules [15].
In the present study, we employed the RT-PCR technique for
the precise localization of AT1 receptor and angiotensinogen
mRNAs in microdissected renal tubules, glomeruli, arcuate
arteries, and vasa recta bundles.
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Methods
Renal tubule microdissection
Male Sprague-Dawley rats weighing 75 to 100 g were killed by
decapitation. The aorta was cannulated with polyethylene tub-
ing below the left kidney, and the left kidney was perfused. The
kidney was perfused initially with 10 ml of ice-cold dissection
solution (solution 1) and then with 10 ml of the same solution
containing 1 mg/mi collagenase (collagenase solution) (type I,
300 u/mg Sigma Chemical, St. Louis, Missouri, USA) and 1
mg/mi bovine serum albumin (Sigma Chemical). The dissection
solution (solution 1) contained the following (in mM): 135
NaCI, 1 Na2SO4, 1.2 MgSO4, 5 KCI, 2 CaC1,, 5.5 glucose, and
5 N-2-hydroxyethyipiperazine-N'-2-ethanesulfonic acid (HEPES,
pH 7.4). The left kidney was removed and a coronal section was
made that contained the entire corticopapillary axis. This
section was cut into three pieces: cortex, outer medulla, and
inner medulla. These pieces were transferred into individual
tubes containing 1 ml of the same collagenase solution as used
to perfuse the kidney. The tubes were incubated for 30 minutes
(cortex and outer medulla) or 40 minutes (inner medulla) at 37°C
in a shaking water bath. The solutions were bubbled with 100%
oxygen during these incubations. Then tissues were transferred
to the dissection solution containing 10 mM vanadyl ribonucie-
otide complex (Life Technologies, Inc., Gaithersburg, Mary-
land, USA), a potent RNase inhibitor, and they were placed on
ice until microdissection.
Following previously described techniques [15], we microdis-
sected the following structures: glomeruli (Gim), proximal
convoluted tubule (PCI), proximal straight tubule (PST), cor-
tical collecting duct (CCD), arcuate artery, outer medullary
collecting duct (OMCD), outer medullary thick ascending limb
(MTAL), inner medullary collecting duct (IMCD), and outer
medullary vasa recta bundle. In the dissection of glomeruli,
care was taken to remove all attached pieces of tubule, as well
as afferent and efferent arterioles. PST and CCD segments were
obtained from medullary rays in cortical slices. Arcuate arteries
were dissected from the junction of cortex and outer stripe of
outer medulla. MTAL, OMCD, and vasa recta were dissected
from the inner stripe of outer medulla. IMCD segments were
dissected from inner medulla.
The lengths of the dissected tubules were measured using a
calibrated eyepiece micrometer. Generally, 5 glomeruli or 2 mm
lengths of the renal tubule segment or arcuate artery were
transferred to each assay tube, as indicated. Because it was
impossible to separate individual vasa recta in a microdissected
vascular bundle, we transferred entire bundles into the assay
tubes for the RT-PCR procedure.
Microdissected structures were transferred to a separate
wash dish using a bent, polished, Pasteur pipette coated with a
0.1% BSA (RNase-free, Boehringer-Mannheim, Germany).
This wash dish contained 10 ml of the dissection solution.
Microdissected tubules, glomeruli, and arcuate arteries and
vasa rectas were washed free of contaminating debris and
vanadyl ribonucleotide complex. These structures were trans-
ferred into the appropriate RT-PCR reaction tube, which con-
tained 10 d of ice-cold dissection solution containing >1 U/1.d
of human placental RNase inhibitor (Boehringer-Mannheim)
and 5 mss dithiothreitol (DTT, Cleland's reagent, USA).
Reverse transcription (Ri)
RT was performed using a cDNA synthesis kit (Boehringer-
Mannheim). The RNase inhibitor solution was removed and 9
d of 2% Triton X- 100, containing >1 U/pJ RNase inhibitor, 5
mM DTT, and 3 U RNase-free DNase (Pharmacia Fine Chem-
icals, USA) were added to permeabilize the cells, and incubated
at 37°C for 30 minutes to digest the genomic DNA. The samples
were heated to 90°C for five minutes to inactivate the DNase.
RI components were added to the reaction tubes as described
previously [151: 4 pi buffer I, I d RNase inhibitor, 2 d
deoxynucleotide mixture, 2 pi random primer, and 2 p1 avian
myeloblastoma virus reverse transcriptase. Reaction tubes
were incubated at 42°C for 60 minutes in a Program Tempcon-
trol System (Astec, Japan). At the end of the incubation period,
the reaction was stopped by heating at 90°C for five minutes.
This heat treatment also denatures RNA-cDNA hybrids and
inactivates the reverse transcriptase. Then the reaction tubes
were placed on ice until the addition of PCR reagents.
Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using the
GeneAmp DNA Amplification Reagent Kit (Perkin-Ermer Ce-
tus, USA), with rat AT1 receptor specific primers prepared on
a DNA synthesizer (Applied Biosystems, Japan). We designed
specific primers of 20 to 25 nucleotides in length with 50 to 60%
GC composition. The resultant high calculated Tm (>75°C)
allows a stringent annealing temperature in the PCR cycle. AT1
receptor primer 1 (antisense) was defined by bases 1044 to 1064,
and primer 2 (sense) encompassed bases 260 to 283 [7]. The
sequence of primer 1 was 5'-CAAGACGCAGGCTTFFTG-
GCC-3', primer 2 was 5'-ATACCGCTATGGAGTACCGC-
TGGC-3'. The predominant cDNA amplification product was
predicted to be 804 bp in length (the distance between primers
plus primer length). A third oligonucleotide was synthesized to
serve as an amplification product-specific probe. This oligonu-
cleotide (sense) included bases 388 to 407 of the cDNA,
positioned between primer 1 and primer 2. The sequence of this
oligonucleotide probe was 5'-ATCGICCACCCAATGAAGTC-
3'.
Angiotensinogen primer 1 (antisense) was defined by bases
1402 to 1421, and primer 2 (sense) encompassed bases 698 to
719 [16]. The sequence of primer 1 was 5'-TGGGGGTTATC-
CACTCTGCC-3', primer 2 was 5'-CIGACCCAGTTCITGCT-
GCC-3'. The predominant cDNA amplification product was
predicted to be 723 bp in length. Angiotensinogen primers 1 and
2 were designed to localize to separate exons [17]. A third
oligonucleotide was synthesized to serve as an amplification
product-specific probe. This oligonucleotide (sense) included
bases 761 to 780 of the cDNA, positioned between primer 1 and
primer 2. The sequence of this oligonucleotide probe was
5'-TGAACTI'GCCACTAGAGGGG-3'.
RI and PCR of giyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) served as a positive control. The primers were
defined by the following cDNA base sequence [181: primer 1
(antisense), bases 795 to 814, sequence, 5'-AGATCCA-
CAACGGATACATT-3'; primer 2 (sense), bases 506 to 525,
sequence, 5'-TCCCTCAAGATTGTCAGCAA-3'. The predom-
inant cDNA amplification product was predicted to be 309 bp in
length. When we used GAPDH as an internal control primers,
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after reverse transcription, we divided 20 pi samples into 15 pi
for angiotensinogen or Ang II receptor and 5 p1 for GAPDH.
The volume was adjusted to 20 p1 with sterile water. Then we
ran parallel PCR reactions with each set of primers.
To carry out the PCR, 80 tl of a PCR master mix, prepared
immediately before and containing all PCR components, were
added to each tube directly. Total PCR volume was then 100 p1,
including the original 20 p1 of RT reaction. Fifty picomoles of
each primers 1 and 2 were used per reaction. Deoxynucleotides
were added to a final concentration of 0.20 mM each. Reaction
buffer (lOx) was diluted (1/10) to have a final composition of: 10
mM Tris-HC1, pH 8.3, 50 m KC1, 1.5 mrvi MgCl2 and 0.001%
(wt/vol) gelatin, and 2.5 units of Taq DNA polymerase.
One hundred microliters of mineral oil were overlayed to
prevent evaporation during the high temperature incubations.
The tubes were placed in the Program Tempcontrol System
programmed as follows. First, incubation was at 94°C for three
minutes (initial melt). Then, 30 cycles of the following sequen-
tial steps were done: 94°C for one minute (melt); 60°C for one
minute (anneal); 72°C for three minutes (extend). Last was an
incubation at 72°C for seven minutes (final extension). Then
samples were kept at 4°C until the time of analysis.
PCR product analysis
Ninety microliters of the total reaction volume was ethanol
precipitated [19]. The PCR products were size-fractionated by
agarose gel electrophoresis. After electrophoresis and ethidium
bromide staining, DNA bands were visualized with an ultravi-
olet transilluminator (Funakoshi, Japan).
For Southern blot analysis, gels were denatured, neutralized,
and blotted onto a nitrocellulose filter (Funakoshi, Japan)
essentially as described by Maniatis, Fritsch and Sambrook
[19], with 20x SSC (standard sodium citrate; composition: 3 M
sodium chloride, 0.3 M sodium citrate, pH 7.0) as the transfer
buffer. Blots were baked at 80°C for four hours to fix the DNA.
The synthetic oligonucleotide probes were end labeled with 32P
as described previously [15], Prehybridization/hybridization
washes were also same as previously described [15].
To confirm that the PCR products were really AT1 receptor
and angiotensinogen eDNAs, the PCR products were se-
quenced. PCR products from PCT were separated by gel
electrophoresis. PCR products of AT1 receptor and angioten-
sinogen were subcloned into pGEM-3Zf(—) vector (Promega,
Wisconsin, USA), then sequenced using the dideoxynucleotide-
chain termination reaction of Sanger, Nicklen and Coulson [20].
Relative quantitation of mRNA levels from autoradiographs
The PCR products of AT1 receptor were detectable from
several nephron segments. The relative amount of PCR prod-
ucts was determined by densitometer scanning of autoradio-
graphs using a laser densitometer (Hoefer Scientific Instru-
ments, San Francisco, California, USA). Each RT-PCR
included one or more glomeruli samples. For relative quantita-
tion, we used the densitometry value from the glomeruli sam-
ples as an internal standard (100%), and calculated the percent-
age of the glomeruli value for each segment.
To test the relationship between the quantity of starting
material and that of amplification product as reflected by
densitometry values, we compared amplification products from
one, three, and five glomeruli.
Statistics
The results were given as means SEM. The differences were
tested using analysis of variance. P < 0.05 was considered
significant.
Results
Effect of reverse transcription on AT1 receptor mRNA
amplification
With reverse transcription, we detected a clear single band,
which was the predicted size of 804 bp (Fig. 1). When the PCR
procedure was carried out in the absence of reverse transcrip-
tion, the 804 bp band was not seen and there was no other
recognizable band. This indicated that the 804 bp band origi-
nated from mRNA, not from genomic DNA, which was pre-
sumably digested by DNase treatment. The Southern blots of
the gels demonstrated specific binding of the oligonucleotide
probe to the 804 bp product, confirming its identity.
Relationship between the quantity of starting material and
that of amplification product for AT1 receptor mRNA
We compared amplification products from one, three, and
five glomeruli (Fig. 2). The data are the mean SEM of five
experiments from five rats. Assigning the five glomeruli sample
as an arbitrary unit of 100, the values obtained were (mean
SEM, N = 5) 18.3 2.1 (1 glomerulus) and 63.1 4.9 (3
glomeruli). Linear regression analysis showed high correlation
between densitometry values and the numbers of glomeruli (r =
0.99). A typical autoradiograph is shown in the upper portion of
Figure 2.
Distribution of AT1 receptor mRNA in microdissected
structures
Each reaction was performed using either 2 mm of tubule
length, five glomeruli, a single vasa recta bundle, or 2 mm
length of arcuate artery (Fig. 3). A single band of predicted size
(804 bp) was consistently found from glomeruli, PCT, PST,
MTAL, CCD, OMCD, IMCD, vasa recta bundle, and arcuate
artery for AT1 receptor (Fig. 3A). The Southern blots of the gels
demonstrated specific binding of the oligonucleotide probe to
the 804 bp product (Fig. 3B). We confirmed that the PCR
product is exactly the expected sequence of the AT1 receptor
cDNA by sequencing of subcloned PCR product.
Among renal nephron segments, the largest signal was con-
sistently found in the glomerulus, PCT, and PST. Furthermore,
a large signal was consistently seen in CCD, vasa recta bundle,
and arcuate artery. Small, but detectable bands were observed
from MTAL, OMCD and IMCD. The amplification product of
GAPDH was detected from all renal structures at the predicted
size (309 bp) and served as a positive control for the RT-PCR
reaction (Fig. 3C).
Relative levels of the AT1 receptor amplfi cation products
among the nephron segments
The densitometer values are presented as percentages of
2-mm PCT value measured in the same experiment (Fig. 4). In
proximal straight tubules, the signal was 93.5 9.5% (vs. PCT,N = 5). Among collecting ducts segments, the values were:
CCD, 86.1 12.9%; OMCD, 51.8 7.5%; and IMCD, 26.8
6.5%. The value in MTAL was 47.4 6.0%.
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Fig. 1. Effect of reverse transcription on AT,
receptor mRNA amplffication. (A) Ethidium
bromide stained agarose gels for AT1
receptor. (B) Autoradiograms of
corresponding Southern blots. The blots were
probed with a 32P-labeled oligonucleotide that
localized between the PCR primers. In each
panel, the left lane is the PCR carried out
with reverse transcription (RT). The right lane








Fig. 2. Densitometric analysis of the
relationship between the quantity of starting
material and the resulting amplification
product for AT, receptor mRNA. The data are
the mean SEM of five experiments from five
rats. An arbitrary value of 100 was assigned
to the sample representing five glomeruli, The
upper portion of the figure is a typical
autoradiogram. From left to right, the bands
originated from one, three, and five glomeruli.
Fig. 3. Detection of AT, receptor mRNA in microdissected renal
structures by RT-PCR. (A) Ethidium bromide stained agarose gels for
AT1 receptor. The arrow indicates expected PCR product size (804 bp).
(B) Autoradiograms of corresponding Southern blots. The blots were
probed with a '2P-labeled oligonucleotide that localized between the
PCR primers. (C) Ethidium bromide stained agarose gel of GAPDH as
positive control primers. The arrow indicates expected PCR product
size (309 bp). Abbreviations are: Glm, glomerulus; PCT, proximal
convoluted tubule; PST, proximal straight tubule; MTAL, medullary
thick ascending limb; CCD, cortical collecting duct; OMCD, outer
medullary collecting duct; IMCD, inner medullary collecting duct; VR
bundle, vasa recta bundle.
Effect of reverse transcription on angiotensinogen mRNA
amplification
With reverse transcription, we detected a clear single band,
which was the predicted size of 723 bp (Fig. 5). When the PCR
procedure was carried out in the absence of reverse transcrip-
tion, the 723 bp band was not seen and there was no other











Each reaction was performed using either 2 mm of tubule
length, five glomeruli, a single vasa recta bundle or 2 mm length
of arcuate artery (Fig. 6). A single band of predicted size (723
bp) was consistently found from glomeruli, PCT, PST, and vasa
recta bundle (Fig. 6A). The Southern blots of the gels demon-
strated specific binding of the oligonucleotide probe to the 723
bp product (Fig. 6B). We confirmed that the PCR product is
exactly the expected sequence of the angiotensinogen cDNA by
sequencing of subcloned PCR product. A large signal was
consistently found in PCT and PST. Small, but detectable bands
were observed from glomerulus and vasa recta bundle. The
amplification product of GAPDH was detected from all renal
structures at the predicted size (309 bp) and served as a positive
control for the RT-PCR reaction (Fig. 6C).
Discussion
Our study documents that AT1 receptor mRNA distributes
widely along nephron segments and renal vascular system, and
that angiotensinogen mRNA is expressed in PCT, PST, glomer-
ulus, and vasa recta bundle.
It is now well established that Ang II can influence proximal
tubule function. We detected a high level of AT1 receptor
mRNA in PCT and PST. Harris and Young [211 demonstrated
that iO—' M to 10—10 M Ang II led to a stimulation of proximal
tubular reabsorption, while l0— M inhibited proximal fluid
absorption. Recently Liu and Cogan [2] indicated that in the
early Si segment of the proximal tubule, Ang II stimulates
Na-H exchange and bicarbonate reabsorption. The mechanism
of Ang II action in proximal tubule is speculated to be inhibition
of adenylate cyclase activity and cAMP accumulation [3]. The
molecular topology of AT1 receptor is that of a G-protein
coupled receptor [6, 71. The action of Ang II to inhibit adenylate
cyclase seems to be mediated by pertussis toxin-sensitive Gi
protein, which may be coupled to AT1 receptor [22]. Our data
confirm angiotensinogen mRNA expression within the proximal







Fig. 4. Relative quantitation of AT, receptor mRNA in renal nephron
segments. The values for each segment are expressed as a percentage of
the value from 2 mm PCT obtained in the same amplification run. The
total number of each segment is five experiments from five rats.
nated from mRNA, not from genomic DNA. The Southern blots
of the gels demonstrated specific binding of the oligonucleotide
probe to the 723 bp product, confirming its identity.
Distribution of angiotensinogen mRNA in microdissected
structures
PCT PST MTAL CCD OMCD IMCD
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Fig. 5. Effect of reverse transcription on angiotensinogen mRNA amplUication. (A) Ethidium bromide stained agarose gels for angiotensinogen.
(B) Autoradiograms of corresponding Southern blots. The blots were probed with a 32P-labeled oligonucleotide that localized between the PCR
primers. In each panel, the left lane is the PCR carried out with reverse transcription (RT). The right lane is the PCR carried out without RT,
tubule, which provides a local source of angiotensinogen.
Immunocytochemical studies suggest that renin and angiotensin
converting enzyme are present in the proximal tubule [231. With
angiotensinogen present in the proximal tubule, renin may
produce local angiotensin I. Angiotensin I could form Ang II via
local angiotensin converting enzyme in the proximal tubule.
Ang II could then have effects on tubular functions through Ang
II receptor.
Although the highest signal of AT1 receptor was found in the
proximal tubule, an appreciable density of specific binding of
Ang II was reported in medullary and cortical thick ascending
limb of the rat kidney [101. This study, however, did not
distinguish between type I and type II receptors [101. Recently,
Ang II was reported to increase cytosolic calcium concentra-
tions via specific receptors in medullary thick ascending limbs
[24]. Our data demonstrate that AT1 receptor is present in
medullary thick ascending limbs, and that Ang II may have
physiological actions via the AT1 receptor. There is not pres-
ently a eDNA for the type II Ang II receptor, and thus its
distribution cannot be approached in this present work.
The interesting point in our results is that a relatively large
amount of AT1 receptor PCR product was detected in CCD.
Early micropuncture studies suggested that Ang II might have a
distal site of action to inhibit reabsorption [25]. Binding study
using microdissection demonstrated that distal convoluted tu-
bule, CCD, and IMCD haa binding activity for Ang II, but this
study could not distinguish between type I and type II receptors
[10]. Our study is the first report which clearly shows that AT1
receptor mRNA is present in the distal nephron. Ang II should
have some effects on tubular function through AT1 receptors in
CCD, OMCD, and IMCD.
The PCR signal of AT1 receptor mRNA in glomeruli and the
vascular system is consistent with the findings of autoradio-
graphic binding studies. Recently Sechi et al [9], Herblin,
Diamond and Timmermans [26], and Gibson et al [27] used
DuP753, a specific antagonist for AT1 receptor to determine the
localization of Ang II receptor subtypes. They found that
DuP753 selectively eliminates '251-Ang II labeling of glomeruli.
Many papers have reported the physiological actions of Ang II
in glomeruli. Infusion of low-dose Ang II into renal arteries
elicits an increase in renal vascular resistance and consequently
a decrease in renal plasma flow [1]. Autoregulation of GFR is
critically dependent on the action of Ang II [1]. Ang II also
influences glomerular mesangial cell function [28, 29]. From our
results, it seems likely that these Ang II effects on the glomer-
ulus are mediated at least in part by AT1 receptors.
Our data indicate that vasa recta and arcuate artery also
possess AT1 receptors. Autoradiographic studies have also
shown that specific binding sites for Ang II are found in outer
medulla, which are thought to be localized on vasa recta bundle
[8, 9]. Since angiotensinogen mRNA is found in vasa recta,
local production of angiotensin is possible in renal medulla.
Renin might reach the medulla via the microcirculation, lym-
phatics, or tubular fluid [30, 31]. Angiotensin converting en-
zyme is found in vascular endothelium. Thus, Ang II might be
produced locally in renal medulla, and may have physiological
effects on renal medullary flow via AT1 receptor.
We applied the RT-PCR technique to detect AT1 receptor
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Fig. 6. Detection of angiotensinogen mRNA
in microdissected renal structures by RT-
PCR. (A) Ethidium bromide stained agarose
gels for angiotensinogen. The arrow indicates
expected PCR product size (723 bp). (B)
Autoradiograms of corresponding Southern
blots. The blots were probed with a 32P-
labeled oligonucleotide that localized between
the PCR primers. (C) Ethidium bromide
stained agarose gel of GAPDH as positive
control primers. The arrow indicates expected
PCR product size (309 bp).
mRNA from microdissected single nephron segments. Usually
PCR amplification from genomic DNA can be distinguished
from PCR products that originate from mRNA by making
primers in different exons [14, 15]. In the case of AT1 receptors,
there is no information about intron. In most of the seven
membrane spanning-type receptors, no intron in the coding
region is reported [32]. To prevent the PCR amplification from
genomic DNA, we treated the sample with RNase-free-DNase
in the presence of RNase inhibitor before reverse transcription.
This treatment breaks only genomic DNA, preserving RNA.
Then we did a heat treatment to inactivate DNase, just before
the reverse transcription. Using this protocol, we detected PCR
products only in the presence of reverse transcription, as shown
in Figure 1. This result indicates that the PCR product origi-
nates from mRNA, not from genomic DNA.
The discrepancies between our results of AT1 receptor
mRNA distribution and the results from autoradiographic stud-
ies [8, 9] might come from the post-transcriptional regulation
and different translational control of mRNA among the nephron
segments. Quantitative changes in gene expression can occur
between the stages of transcription and translation. Several
regulations are known in RNA processing from nuclear RNA to
cytoplasmic mRNA. This means that the level of transcription
is not the sole factor responsible for establishing the level of
mRNA. Changes in stability or in the efficiency of RNA
processing could intervene to alter the relative abundance of
cytoplasmic mR A. Differential stabilization or destabilization
of mRNA by hjrnones, translation products, and ligands has
been demonstrahd [33]. Rates of protein synthesis are deter-
mined both by mRNA levels and by the translational efficiency
of the mRNA. The mechanism of translational regulation is net
well-known. In case of ferritin, translational regulation was
reported to be mediated by iron-activated binding of cytoplas-
mic regulatory proteins to the 5' flanking region present in the
mRNA of ferritin [34]. Several mechanisms for regulating the
rate of translation can be envisioned, and the overall rate of
mRNA translation is known to vary under several conditions.
These mechanisms of post-transcriptional regulation are not
known about AT1 receptor. Therefore, it seems very difficult to
speculate the relationship between the amount of mRNA level
and the number of receptor present in cell surface in the
nephron segments. Therefore, further investigations will be
necessary to clarify the discrepancies between AT1 mRNA
distribution and the results from autoradiographic studies [8, 91.
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Approaches to relative or absolute quantitation of RT-PCR
have been previously proposed, including competitive PCR [35]
and PATTY (PCR aided transcript titration assay) [36]. Com-
petitive PCR does not account for the efficiency of the reverse
transcription step and can give only relative, rather than abso-
lute, quantitation of the number of niRNA molecules originally
present. PATTY is similar to competitive PCR, except that the
internal standard is RNA. It is unclear whether the approach
would give adequate quantitation in microdissected tubules,
since the efficiency of reverse transcription may be different
between endogenous mRNA and the exogenous standards.
We chose a simple approach to relative quantitation rather
than any of the complicated alternatives. We believe that our
method gives a relative measure of the amount of AT1 receptor
mRNA initially present in the cells. This conclusion is based on
the observation that there is an approximately linear relation-
ship between the number of glomeruli used for the assay (that
is, the amount of starting material) and the value obtained from
densitometry of the amplification product band.
We make relative quantitation of PCR product of each
nephron segments per length. It is technically possible to
measure DNA contents per mm in each nephron segments, and
adjust densitometory values from PCR products by DNA
amounts. We selected our methods to express densitometory
values per mm of tubule length or number of glomeruli because
many physiological studies, such as microperfusion [2, 3] and
microdissection studies [101, have been expressed per mm
tubule segments. We especially wanted to compare our results
with the Ang II binding study by Mujais et al [101, which
demonstrated Ang II binding to each nephron segments per
length. If we define the relationship between gene expression
and physiological function, both must be in comparable terms.
In summary, our data show that Ang II could be produced
locally in the proximal tubule and vasa recta bundle, and AT1
receptors were widely distributed not only in the glomerulus
and vessels but also tubules from PCT to IMCD. Ang II is
known to have effects on fluid transport in proximal tubules.
Ang II may also have some effects on tubular function through
AT1 receptors at distal nephron segments.
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